Novartis to Begin Selling Copy of Amgen's Neupogen in US
September 03 2015 - 2:49AM
Dow Jones News
By Neil MacLucas
ZURICH-Novartis AG (NVS) Thursday said it will begin selling the
first biosimilar drug in the U.S. after an appeals court in
Washington rejected a request to block the Swiss drug maker's sale
of its copycat version of Amgen Inc.'s blockbuster remedy,
Neupogen.
Basel-based Novartis's move followed the decision Wednesday by
the U.S. Court of Appeals for the Federal Circuit which has cleared
the way for the firm's Sandoz unit to start selling Zarxio, a
knockoff version of Neupogen that was approved by the U.S. Food and
Drug Administration in March. The U.S. market accounted for more
than 70% of Amgen's $1.16 billion in global sales of Neupogen last
year, a drug for treating chemotherapy patients.
Zarxio was the first biosimilar--a copy of a biotechnology
drug--approved by the FDA under abbreviated criteria enabled by a
provision of the 2010 Affordable Care Act. However the product's
introduction has been delayed by a legal dispute between Amgen and
Novartis.
Novartis hasn't announced a price for Zarxio. In Europe, where
biosimilars have been available for several years, they typically
cost 15% to 30% less than the original brands.
Write to Neil MacLucas at neil.maclucas@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 03, 2015 02:34 ET (06:34 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024